Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.

Learn more


For information relating to investor updates, financial information, share trading and presentations click the link below.

Investor News


Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Learn more

Hexima to attend ASM Microbe 2016

Hexima’s Chief Science Officer, Professor Marilyn Anderson, and Onychomycosis Project Leader, Dr Michael Baker, will attend ASM Microbe 2016, held in Boston in June, to present Hexima’s antifungal technology. The conference will be an opportunity to showcase the...

Board and Management Update

The Board is pleased to advise shareholders of changes to the Company’s Board and to the management structure of Hexima.  Please click on the link below for details. Hexima Board and Management Update Dec...

AGM 2015

Presentations and scripts from the 2015 Hexima AGM. Chairman's speech Chief Operating Officer's speech Chief Operating Officer's presentation Results of...

Notice of Annual General Meeting 2015

NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited ABN 64 079 319 314 (“Company”) will be held at the KPMG Theatrette, Ground Floor, 147 Collins Street, Melbourne, Victoria on Wednesday 18 November 2015 at 11am. Hexima -...

Results of Bookbuild

The Bookbuild conducted by Taylor Collison has now closed.  We have been informed by Taylor Collison that 160,750 shares were matched and traded at the final Bookbuild price of $0.20 per share.

External Links

Take a look at these useful links to learn more about our industry.